X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DR. REDDYS LAB - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DR. REDDYS LAB LUPIN LTD/
DR. REDDYS LAB
 
P/E (TTM) x 20.3 30.5 66.6% View Chart
P/BV x 2.8 3.0 92.1% View Chart
Dividend Yield % 0.9 0.9 100.7%  

Financials

 LUPIN LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
DR. REDDYS LAB
Mar-17
LUPIN LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,7503,397 51.5%   
Low Rs1,3842,560 54.0%   
Sales per share (Unadj.) Rs387.4856.5 45.2%  
Earnings per share (Unadj.) Rs56.678.0 72.6%  
Cash flow per share (Unadj.) Rs76.8139.9 54.9%  
Dividends per share (Unadj.) Rs7.5020.00 37.5%  
Dividend yield (eoy) %0.50.7 71.3%  
Book value per share (Unadj.) Rs298.9739.8 40.4%  
Shares outstanding (eoy) m451.58165.74 272.5%   
Bonus/Rights/Conversions ESOPSBB-  
Price / Sales ratio x4.03.5 116.3%   
Avg P/E ratio x27.738.2 72.4%  
P/CF ratio (eoy) x20.421.3 95.8%  
Price / Book Value ratio x5.24.0 130.2%  
Dividend payout %13.225.7 51.6%   
Avg Mkt Cap Rs m707,513493,632 143.3%   
No. of employees `00016.822.7 74.0%   
Total wages/salary Rs m28,49531,068 91.7%   
Avg. sales/employee Rs Th10,418.36,259.0 166.5%   
Avg. wages/employee Rs Th1,697.01,369.8 123.9%   
Avg. net profit/employee Rs Th1,523.0569.7 267.3%   
INCOME DATA
Net Sales Rs m174,943141,961 123.2%  
Other income Rs m1,0651,715 62.1%   
Total revenues Rs m176,008143,676 122.5%   
Gross profit Rs m44,93124,722 181.7%  
Depreciation Rs m9,12210,266 88.9%   
Interest Rs m1,525634 240.6%   
Profit before tax Rs m35,34915,537 227.5%   
Minority Interest Rs m-720-   
Prior Period Items Rs m83349 23.6%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7852,965 330.0%   
Profit after tax Rs m25,57512,921 197.9%  
Gross profit margin %25.717.4 147.5%  
Effective tax rate %27.719.1 145.1%   
Net profit margin %14.69.1 160.6%  
BALANCE SHEET DATA
Current assets Rs m119,54296,837 123.4%   
Current liabilities Rs m61,20684,199 72.7%   
Net working cap to sales %33.38.9 374.6%  
Current ratio x2.01.2 169.8%  
Inventory Days Days7673 103.6%  
Debtors Days Days9098 92.0%  
Net fixed assets Rs m131,660102,552 128.4%   
Share capital Rs m903829 109.0%   
"Free" reserves Rs m134,073121,792 110.1%   
Net worth Rs m134,976122,621 110.1%   
Long term debt Rs m56,4785,449 1,036.5%   
Total assets Rs m266,073218,165 122.0%  
Interest coverage x24.225.5 94.8%   
Debt to equity ratio x0.40 941.6%  
Sales to assets ratio x0.70.7 101.0%   
Return on assets %10.26.2 163.9%  
Return on equity %18.910.5 179.8%  
Return on capital %19.312.9 149.4%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m81,88581,670 100.3%   
Fx outflow Rs m21,50626,355 81.6%   
Net fx Rs m60,37855,315 109.2%   
CASH FLOW
From Operations Rs m41,14821,444 191.9%  
From Investments Rs m-25,287-18,404 137.4%  
From Financial Activity Rs m4,332-3,692 -117.3%  
Net Cashflow Rs m20,193-1,144 -1,765.1%  

Share Holding

Indian Promoters % 46.6 25.5 182.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 31.9 35.3 90.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.1 15.3 66.0%  
Shareholders   98,259 75,885 129.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS